Cellens, Inc

Cellens, Inc. is a cancer diagnostics company that has developed an AI-driven mechanobiology platform, known as BioFeel, for non-invasive cancer detection. The platform works by using atomic force microscopy to analyze the physical properties and mechanical characteristics of individual cells extracted from bodily fluids, such as voided urine. By uncovering unique biophysical markers at the nanoscale, the company’s machine learning algorithms generate a biophysical fingerprint of disease. This approach enables the direct measurement of cellular stiffness and other mechanical changes that occur during malignant transformation, providing a diagnostic alternative to traditional molecular tests that search for genetic or protein traces.

The company's technology aims to improve the standard of care for cancer monitoring, particularly for bladder cancer recurrence surveillance, where current molecular diagnostics often struggle to detect low-grade tumors. By offering a non-invasive, accurate testing method, Cellens seeks to help clinicians make timely treatment decisions, potentially reducing the need for invasive procedures. Supported by clinical data indicating high sensitivity and specificity in detecting bladder cancer recurrence, the company is actively collaborating with industry partners and academic institutions to scale its platform for broad oncological applications, including drug efficacy testing and minimal residual disease monitoring.